More on the Ebola Crisis

The current Ebola outbreak has raised many issues pertaining to our current drug development and approval process.  The WHO has issued a statement regarding the ethics for use of experimental drugs in patients infected with Ebola (http://www.nature.com/news/should-experimental-drugs-be-used-in-the-ebola-outbreak-1.15698).  A major concern is whether or not these drugs are effective (http://www.nytimes.com/2014/08/21/business/drug-used-for-ebola-related-virus-shows-promise.html?_r=0).  Unfortunately, cases of fraudulent claims have been reported by the FDA (http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm410086.htm).  Since our current supply is limited, what criteria should be used in deciding which patients will receive the drug (http://www.nature.com/news/scale-up-the-supply-of-experimental-ebola-drugs-1.15736)?.  Finally, how do we better protect the health care workers (http://www.the-scientist.com/?articles.view/articleNo/40864/title/Ebola-s-Toll-on-Healthcare-Workers/)?